Clinical Trial

Effectiveness of DIR/Floortime™ in Children With Autism Spectrum Disorder

Study acronym: DIR-ASD
Completed
View on ClinicalTrials.gov →
Summary
This randomized controlled trial evaluates the efficacy of Integrated DIR/Floortime™ in improving functional emotional development and adaptive behavior in children aged 4-12 years with Autism Spectrum Disorder (ASD). Participants are randomly assigned to either an intervention group receiving DIR/Floortime™ in addition to their ongoing standard therapies or a control group receiving standard therapies alone. Functional emotional development is assessed using the Functional Emotional Assessment Scale (FEAS), while adaptive behavior is evaluated using the Vineland Adaptive Behavior Scales (VABS). The study aims to determine whether integrating DIR/Floortime™ leads to greater improvements in emotional, social, communication, and adaptive functioning compared with standard interventions alone.
Trial Details
NCT Number NCT07758465
Lead Sponsor Fatima Tabassum
Conditions Autism Spectrum Disorder (ASD
Enrollment 14 participants
Start Date 2026-02-15
Primary Completion 2026-07-20 (estimated)
Study Completion 2026-08-04 (estimated)
Updated on ClinicalTrials.gov 2026-08-13